P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. (2nd July 2019) - Knox, J; Cheng, A; Cleary, S; Galle, P; Kokudo, N; Lencioni, R; Park, J; Zhou, J; Mann, H; Morgan, S; Liu, X; Chin, S; et al.